Specific targeting of the IL-23 receptor, using a novel small peptide noncompetitive antagonist, decreases the inflammatory response.
about
Cytokines in psoriasisIL23R (Interleukin 23 Receptor) Variants Protective against Inflammatory Bowel Diseases (IBD) Display Loss of Function due to Impaired Protein Stability and Intracellular Trafficking.Release of anti-inflammatory peptides from thermosensitive nanoparticles with degradable cross-links suppresses pro-inflammatory cytokine production.Efficacy and safety of ustekinumab in adolescents.
P2860
Specific targeting of the IL-23 receptor, using a novel small peptide noncompetitive antagonist, decreases the inflammatory response.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Specific targeting of the IL-2 ...... ses the inflammatory response.
@en
Specific targeting of the IL-2 ...... ses the inflammatory response.
@nl
type
label
Specific targeting of the IL-2 ...... ses the inflammatory response.
@en
Specific targeting of the IL-2 ...... ses the inflammatory response.
@nl
prefLabel
Specific targeting of the IL-2 ...... ses the inflammatory response.
@en
Specific targeting of the IL-2 ...... ses the inflammatory response.
@nl
P2093
P2860
P1476
Specific targeting of the IL-2 ...... ses the inflammatory response.
@en
P2093
Atefeh Erfani
Christiane Quiniou
Claudine Beauchamp
Durgajini Sivanesan
Frank Cloutier
Gaëlle Chognard
Guy Charron
Jamila Ennaciri
José Carlos Rivera
Maria Domínguez-Punaro
P2860
P304
P356
10.1152/AJPREGU.00540.2013
P577
2014-08-20T00:00:00Z